[go: up one dir, main page]

TR200002938T2 - Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı - Google Patents

Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı

Info

Publication number
TR200002938T2
TR200002938T2 TR2000/02938T TR200002938T TR200002938T2 TR 200002938 T2 TR200002938 T2 TR 200002938T2 TR 2000/02938 T TR2000/02938 T TR 2000/02938T TR 200002938 T TR200002938 T TR 200002938T TR 200002938 T2 TR200002938 T2 TR 200002938T2
Authority
TR
Turkey
Prior art keywords
fusion proteins
tuberculosis antigens
microbacterial
tuberculosis
antigens
Prior art date
Application number
TR2000/02938T
Other languages
English (en)
Inventor
W. Yasir Skeiky A.
Alderson Mark
Campos-Neto Antonio
Original Assignee
Corixa Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/056,556 external-priority patent/US6350456B1/en
Priority claimed from US09/223,040 external-priority patent/US6544522B1/en
Application filed by Corixa Corporation filed Critical Corixa Corporation
Publication of TR200002938T2 publication Critical patent/TR200002938T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Mevcut bulus, en az iki Mycobacterium tuberculosis antijeni içeren füzyon proteinleri ile ilgilidir. Özellikle, iki ayri M. tuberculosis antijen içeren bi-füzyon proteinleri, üç M. tuberculosis antijeni içeren tri-füzyon proteinleri, dört M. tuberculosis antijeni içeren tetrafüzyon proteinleri ve bes M. tuberculosis antijeni içeren penta-füzyon proteinleri ve bunlarin tüberküloz enfeksiyonunun tani, tedavi ve önlemesinde kullanilmasi için metotlar ile ilgilidir.
TR2000/02938T 1998-04-07 1999-04-07 Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı TR200002938T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/056,556 US6350456B1 (en) 1997-03-13 1998-04-07 Compositions and methods for the prevention and treatment of M. tuberculosis infection
US09/223,040 US6544522B1 (en) 1998-12-30 1998-12-30 Fusion proteins of mycobacterium tuberculosis antigens and their uses

Publications (1)

Publication Number Publication Date
TR200002938T2 true TR200002938T2 (tr) 2001-02-21

Family

ID=26735428

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02938T TR200002938T2 (tr) 1998-04-07 1999-04-07 Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı

Country Status (17)

Country Link
US (2) US7186412B1 (tr)
EP (1) EP1068329A2 (tr)
JP (2) JP4227302B2 (tr)
KR (2) KR100692227B1 (tr)
CN (2) CN1629185B (tr)
AU (1) AU753995B2 (tr)
BR (1) BR9909472A (tr)
CA (1) CA2326598C (tr)
CZ (1) CZ302870B6 (tr)
HU (1) HU228354B1 (tr)
IL (1) IL138809A0 (tr)
NO (2) NO332500B1 (tr)
NZ (1) NZ507378A (tr)
PL (1) PL202844B1 (tr)
SA (1) SA99200488B1 (tr)
TR (1) TR200002938T2 (tr)
WO (1) WO1999051748A2 (tr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou
ES2333073T3 (es) 1998-11-04 2010-02-16 Isis Innovation Limited Prueba diagnostica de tuberculosis.
US6448234B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6555115B1 (en) 1998-12-08 2003-04-29 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US6447779B1 (en) 1998-12-08 2002-09-10 Corixa Corporation Compounds for the diagnosis of Chlamydial infection
US6432916B1 (en) 1998-12-08 2002-08-13 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US20030027774A1 (en) * 1999-03-18 2003-02-06 Ronald C. Hendrickson Tuberculosis antigens and methods of use therefor
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US7009042B1 (en) 1999-10-07 2006-03-07 Corixa Corporation Methods of using a Mycobacterium tuberculosis coding sequence to facilitate stable and high yield expression of the heterologous proteins
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
DE60033583T2 (de) * 1999-10-07 2007-09-13 Corixa Corp. CSC, Wilmington Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen
US6316205B1 (en) 2000-01-28 2001-11-13 Genelabs Diagnostics Pte Ltd. Assay devices and methods of analyte detection
AU2001241738A1 (en) 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
WO2001081379A2 (en) 2000-04-21 2001-11-01 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
EP1542732B1 (en) 2000-06-20 2009-09-16 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US6841159B2 (en) 2002-01-30 2005-01-11 The United States Of America As Represented By The Secretary Of The Navy Rapid lateral flow assay for determining exposure to Mycobacterium tuberculosis and other mycobacteria
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
US20120027841A1 (en) 2004-01-07 2012-02-02 Biomedical Research Models, Inc. Novel mucosal vaccination approach for herpes simplex virus type-2
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US8475735B2 (en) 2004-11-01 2013-07-02 Uma Mahesh Babu Disposable immunodiagnostic test system
EP1812580B1 (en) 2004-11-16 2014-12-17 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
CN100368437C (zh) * 2005-01-28 2008-02-13 中国农业科学院哈尔滨兽医研究所 一种诊断牛结核病的重组抗原蛋白及其制备方法
DK2426141T3 (da) 2005-04-29 2014-11-10 Glaxosmithkline Biolog Sa Fremgangsmåde til forebyggelse eller behandling af M tuberkuloseinfektioner
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
CN101311189B (zh) * 2006-06-06 2010-09-08 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101311190B (zh) * 2006-06-06 2011-08-03 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN101298471B (zh) * 2006-06-06 2011-01-19 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
CN100415771C (zh) * 2006-06-06 2008-09-03 中国人民解放军第二军医大学 激发人体抗结核杆菌的保护性免疫反应的抗原表位及其用途
EP2040745B1 (en) * 2006-06-28 2012-12-05 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
FI2068918T4 (fi) 2006-09-26 2024-08-16 Access To Advanced Health Inst Synteettistä adjuvanttia sisältävä rokotekoostumus
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
EP2086582B1 (en) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Vaccine comprising an oil in water emulsion adjuvant
EA021391B1 (ru) 2007-03-02 2015-06-30 Глаксосмитклайн Байолоджикалс С.А. Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
JP5378350B2 (ja) * 2007-04-04 2013-12-25 インフェクティアス ディジーズ リサーチ インスティチュート 結核菌（Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ）ポリペプチドおよびその融合物を含む免疫原性組成物
WO2009049097A1 (en) * 2007-10-13 2009-04-16 Cornell University Compositions for eliciting an immune response against mycobacterium avium subspecies paratuberculosis
KR101378240B1 (ko) 2008-02-22 2014-03-28 포항공과대학교 산학협력단 결핵 예방용 조성물
WO2010104749A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
BRPI0916704A2 (pt) 2008-07-25 2020-08-18 Glaxosmithkline Biologicals S.A. composições farmacêutica, e imunogênica, usos de um polipeptídeo, e de um polinucleotídeo, proteína de fusão, e, polinucleotídeo
PL2315773T3 (pl) * 2008-07-25 2017-07-31 Glaxosmithkline Biologicals S.A. Polipeptydy, polinukleotydy i kompozycje do stosowania w leczeniu utajonej gruźlicy
ES2647321T3 (es) 2008-07-25 2017-12-20 Glaxosmithkline Biologicals S.A. Composiciones y procedimientos novedosos
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
DK3138854T3 (da) 2009-03-10 2022-04-11 Baylor Res Institute Antistoffer mod CD40
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
MY156697A (en) 2010-01-27 2016-03-15 Glaxosmithkline Biolog Sa Modified tuberculosis antigens
UA110118C2 (uk) 2010-12-14 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
CN102154324B (zh) * 2010-12-29 2012-11-28 兰州大学 结核分枝杆菌融合蛋白Mtb10.4-Hsp16.3的构建、表达和纯化方法及其应用
EP2688592A4 (en) 2011-03-25 2015-07-22 Baylor Res Inst Compositions and methods for immunization against the hepatitis C virus
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
CN102305855A (zh) * 2011-05-19 2012-01-04 中山大学 体外检测结核分枝杆菌感染的试剂和方法
WO2013063059A1 (en) * 2011-10-24 2013-05-02 University Of Central Florida Research Foundation, Inc. Plastid-expressed mycobacterium tuberculosis vaccine antigens esat-6 and mtb72f fused to cholera toxin b subunit
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
MX347154B (es) 2012-02-24 2017-02-21 Centro De Investigación Científica Y De Educación Superior De Ensenada Baja California (Cicese) Prueba de diagnóstico para enfermedades infecciosas en ganado bovino.
BR112014028476A2 (pt) 2012-05-16 2017-08-01 Immune Design Corp fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
CN102757971B (zh) * 2012-08-07 2013-09-11 中国人民解放军第三O九医院 一种结核分枝杆菌重组蛋白质及其制备方法
IN2015DN03962A (tr) * 2012-10-23 2015-10-02 Statens Seruminstitut
CA2897398A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Use of vaccines for the treatment of herpes simplex virus type 2 infections
CN105025921B (zh) * 2013-03-15 2019-02-19 宾夕法尼亚大学理事会 用于结核病的预防或治疗的合成免疫原
WO2014172637A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
BR112016015422A2 (pt) 2013-12-31 2017-10-24 Infectious Disease Res Inst formulações de vacina de frasco único
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA3014458A1 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017176076A1 (en) 2016-04-06 2017-10-12 Ewha University - Industry Collaboration Foundation A peptide with ability to penetrate cell membrane
IL319503A (en) 2016-05-16 2025-05-01 Access To Advanced Health Inst PEGylated liposomes and methods of use
CA3023968A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
IL315825A (en) 2016-06-01 2024-11-01 Access To Advanced Health Inst Nanoalum particles containing a fixing factor
IL271384B2 (en) 2017-06-15 2025-02-01 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and their uses
JP7339942B2 (ja) 2017-09-08 2023-09-06 アクセス ツー アドバンスト ヘルス インスティチュート サポニンを含むリポソーム製剤および使用方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN109825497A (zh) * 2019-01-25 2019-05-31 石河子大学 一种新型结核杆菌融合菌株的制备方法及其应用
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
AU2023336224A1 (en) 2022-09-09 2025-03-27 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN118652311B (zh) * 2024-07-17 2025-02-25 扬州大学 结核分枝杆菌复合体ⅶ型分泌系统效应蛋白cfp10保守功能性b细胞表位及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU5741590A (en) 1989-05-04 1990-11-29 Southern Research Institute Improved encapsulation process and products therefrom
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
JPH06510278A (ja) 1991-06-05 1994-11-17 ユニバーシティ オブ コネチカット 分泌タンパク質をコードする遺伝子の標的への配達
ATE186749T1 (de) * 1991-08-15 1999-12-15 Hoffmann La Roche Primerpaar zum nachweis von mycobacterium
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
DK79893D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
DK79793D0 (da) * 1993-07-02 1993-07-02 Statens Seruminstitut Diagnostic test
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK2154248T3 (da) * 1995-09-01 2012-01-30 Corixa Corp Forbindelser og fremgangsmåder til diagnose af tuberkulose
CZ300953B6 (cs) * 1995-09-01 2009-09-23 Corixa Corporation Polypeptid, farmaceutický prostredek a vakcína s jeho obsahem, zpusob prípravy a použití polypeptidu, DNA molekula a její použití, expresní vektor, hostitelská bunka, fúsní protein a diagnostický kit
US6627198B2 (en) * 1997-03-13 2003-09-30 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis antigens and their uses
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
CZ302870B6 (cs) 1998-04-07 2011-12-28 Corixa Corporation Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou

Also Published As

Publication number Publication date
CN1629185B (zh) 2011-11-02
SA99200488B1 (ar) 2006-08-12
EP1068329A2 (en) 2001-01-17
US7186412B1 (en) 2007-03-06
JP4326008B2 (ja) 2009-09-02
HU228354B1 (en) 2013-03-28
CZ20003652A3 (en) 2001-05-16
NO20005050L (no) 2000-11-30
WO1999051748A9 (en) 2000-08-10
NO20120621L (no) 2000-11-30
AU3481799A (en) 1999-10-25
IL138809A0 (en) 2001-10-31
JP2002510494A (ja) 2002-04-09
PL344142A1 (en) 2001-10-08
CA2326598C (en) 2014-06-10
CA2326598A1 (en) 1999-10-14
NO332500B1 (no) 2012-10-01
HUP0101521A2 (hu) 2001-08-28
BR9909472A (pt) 2001-09-11
WO1999051748A2 (en) 1999-10-14
AU753995B2 (en) 2002-10-31
US20060171965A1 (en) 2006-08-03
PL202844B1 (pl) 2009-07-31
KR20060064698A (ko) 2006-06-13
CN1629185A (zh) 2005-06-22
HUP0101521A3 (en) 2004-10-28
CN1163602C (zh) 2004-08-25
KR20010071138A (ko) 2001-07-28
KR100692227B1 (ko) 2007-03-09
US7261897B2 (en) 2007-08-28
WO1999051748A3 (en) 2000-02-03
KR100797876B1 (ko) 2008-01-24
NO20005050D0 (no) 2000-10-06
JP2006273858A (ja) 2006-10-12
JP4227302B2 (ja) 2009-02-18
CN1304451A (zh) 2001-07-18
CZ302870B6 (cs) 2011-12-28
NZ507378A (en) 2002-12-20

Similar Documents

Publication Publication Date Title
TR200002938T2 (tr) Mikrobakteri tüberküloz antijenlerinin füzyon proteinleri ve bunların kullanımı
Hanff et al. Humoral immune response in human syphilis to polypeptides of Treponema pallidum.
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
Poles et al. Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood γδ T cells despite suppressive therapy
TR200806258T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
ATE362379T1 (de) Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
DE3861132D1 (de) Dismulgierendes und reinigungsmittel, verwendbar zur trennung von erdoel-wasser-gemischen, gegebenenfalls emulsionen und anwendungen dieses mittels.
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
BR9814432A (pt) Composições derivadas de mycobacterium vaccae e processo para seu uso
PT845998E (pt) Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
DK0749481T3 (da) Humaniserede monoklonale antistoffer mod human interleukin-4
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
EP0906335A4 (en) Ebv ctl epitopes
ATE125870T1 (de) Hiv-spezifische monoklonale antikörper und hybridome zu ihrer herstellung.
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
FR2752425B1 (fr) Fragments d'acides nucleiques specifiques de mycobacteries membres du complexe m. tuberculosis et leurs applications pour la detection et le diagnostic differentiel des membres du complexe m. tuberculosis
DE69927794D1 (de) Zusammensetzungen zum nachweis und zur diagnose von infektiösen mykobakteriellen krankheiten
FR2608767B1 (fr) Procede pour la detection et le dosage des anticorps anti-(sporozoaires de p. falciparum) dans le sang humain et trousses de diagnostic pour mettre en oeuvre ce procede
KR920700698A (ko) 아메리카 자리콩 항바이러스성 단백질-모노클로날항체 결합체
FI971879L (fi) Allogeenisten ja ksenogeenisten proteiinien vasta-aineet, niiden käyttö diagnoosissa ja hoidossa ja menetelmät niiden määrittämiseksi
DK0929812T3 (da) Diagnosehjælpemiddel samt fremgangsmåde til påvisning af drægtighed af drøvtyggere